Cargando…

Early Humoral Responses of Hemodialysis Patients After Inactivated SARS-CoV-2 Vaccination

PURPOSE: To detect antibody responses to inactivated severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccine in patients undergoing hemodialysis and to investigate vaccine-related adverse events. PATIENTS AND METHODS: A total of 120 hemodialysis (HD) patients and 24 healthy controls (HC...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhao, Wen-Man, Shi, Rui, Wang, Peng, He, Jun, Chen, Yue, Feng, Ya-Ting, Pan, Hai-Feng, Wang, De-Guang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9206439/
https://www.ncbi.nlm.nih.gov/pubmed/35726214
http://dx.doi.org/10.2147/JIR.S361621
_version_ 1784729337828737024
author Zhao, Wen-Man
Shi, Rui
Wang, Peng
He, Jun
Chen, Yue
Feng, Ya-Ting
Pan, Hai-Feng
Wang, De-Guang
author_facet Zhao, Wen-Man
Shi, Rui
Wang, Peng
He, Jun
Chen, Yue
Feng, Ya-Ting
Pan, Hai-Feng
Wang, De-Guang
author_sort Zhao, Wen-Man
collection PubMed
description PURPOSE: To detect antibody responses to inactivated severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccine in patients undergoing hemodialysis and to investigate vaccine-related adverse events. PATIENTS AND METHODS: A total of 120 hemodialysis (HD) patients and 24 healthy controls (HCs) who had not been previously infected with SARS-CoV-2 and had received their first dose of the inactivated vaccine (CoronaVac; Sinovac Biotech Ltd) were recruited for this study. All participants were scheduled to receive a second dose of inactivated SARS-CoV-2 vaccine. Serum-specific immunoglobulin M (IgM) and immunoglobulin G (IgG) antibodies against the SARS-CoV-2 were detected at least 14 days after the second dose of vaccine using a commercial kit. Positive and negative results were defined as a sample/cutoff (S/CO) ratio≥1.00 and <1.00, respectively. Vaccination-related adverse events were assessed using a standardized questionnaire. RESULTS: There were no significant differences regarding the seroprevalences of IgG and IgM antibodies against SARS-CoV-2 and the self-reported vaccination-related adverse events between HD patients and HCs. The analysis results for HD patients suggest that 82 (68.3%) and 27 (22.5%) tested positive for IgG and IgM, respectively. The levels of IgG were higher than IgM levels (P<0.0001). In addition, the IgG-positive group had significantly higher serum albumin levels than the IgG-negative group (P<0.05). Only mild vaccine-related adverse events were observed in two patients (1.66%) and in one healthy individual (4.2%). CONCLUSION: The seroprevalences of IgG and IgM antibodies against SARS-CoV-2 and vaccination-related adverse effects are similar between HD and HCs. The inactivated SARS-CoV-2 vaccine is effective and safe in inducing near-term immunity in hemodialysis patients.
format Online
Article
Text
id pubmed-9206439
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Dove
record_format MEDLINE/PubMed
spelling pubmed-92064392022-06-19 Early Humoral Responses of Hemodialysis Patients After Inactivated SARS-CoV-2 Vaccination Zhao, Wen-Man Shi, Rui Wang, Peng He, Jun Chen, Yue Feng, Ya-Ting Pan, Hai-Feng Wang, De-Guang J Inflamm Res Original Research PURPOSE: To detect antibody responses to inactivated severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccine in patients undergoing hemodialysis and to investigate vaccine-related adverse events. PATIENTS AND METHODS: A total of 120 hemodialysis (HD) patients and 24 healthy controls (HCs) who had not been previously infected with SARS-CoV-2 and had received their first dose of the inactivated vaccine (CoronaVac; Sinovac Biotech Ltd) were recruited for this study. All participants were scheduled to receive a second dose of inactivated SARS-CoV-2 vaccine. Serum-specific immunoglobulin M (IgM) and immunoglobulin G (IgG) antibodies against the SARS-CoV-2 were detected at least 14 days after the second dose of vaccine using a commercial kit. Positive and negative results were defined as a sample/cutoff (S/CO) ratio≥1.00 and <1.00, respectively. Vaccination-related adverse events were assessed using a standardized questionnaire. RESULTS: There were no significant differences regarding the seroprevalences of IgG and IgM antibodies against SARS-CoV-2 and the self-reported vaccination-related adverse events between HD patients and HCs. The analysis results for HD patients suggest that 82 (68.3%) and 27 (22.5%) tested positive for IgG and IgM, respectively. The levels of IgG were higher than IgM levels (P<0.0001). In addition, the IgG-positive group had significantly higher serum albumin levels than the IgG-negative group (P<0.05). Only mild vaccine-related adverse events were observed in two patients (1.66%) and in one healthy individual (4.2%). CONCLUSION: The seroprevalences of IgG and IgM antibodies against SARS-CoV-2 and vaccination-related adverse effects are similar between HD and HCs. The inactivated SARS-CoV-2 vaccine is effective and safe in inducing near-term immunity in hemodialysis patients. Dove 2022-06-14 /pmc/articles/PMC9206439/ /pubmed/35726214 http://dx.doi.org/10.2147/JIR.S361621 Text en © 2022 Zhao et al. https://creativecommons.org/licenses/by-nc/3.0/This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/ (https://creativecommons.org/licenses/by-nc/3.0/) ). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php).
spellingShingle Original Research
Zhao, Wen-Man
Shi, Rui
Wang, Peng
He, Jun
Chen, Yue
Feng, Ya-Ting
Pan, Hai-Feng
Wang, De-Guang
Early Humoral Responses of Hemodialysis Patients After Inactivated SARS-CoV-2 Vaccination
title Early Humoral Responses of Hemodialysis Patients After Inactivated SARS-CoV-2 Vaccination
title_full Early Humoral Responses of Hemodialysis Patients After Inactivated SARS-CoV-2 Vaccination
title_fullStr Early Humoral Responses of Hemodialysis Patients After Inactivated SARS-CoV-2 Vaccination
title_full_unstemmed Early Humoral Responses of Hemodialysis Patients After Inactivated SARS-CoV-2 Vaccination
title_short Early Humoral Responses of Hemodialysis Patients After Inactivated SARS-CoV-2 Vaccination
title_sort early humoral responses of hemodialysis patients after inactivated sars-cov-2 vaccination
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9206439/
https://www.ncbi.nlm.nih.gov/pubmed/35726214
http://dx.doi.org/10.2147/JIR.S361621
work_keys_str_mv AT zhaowenman earlyhumoralresponsesofhemodialysispatientsafterinactivatedsarscov2vaccination
AT shirui earlyhumoralresponsesofhemodialysispatientsafterinactivatedsarscov2vaccination
AT wangpeng earlyhumoralresponsesofhemodialysispatientsafterinactivatedsarscov2vaccination
AT hejun earlyhumoralresponsesofhemodialysispatientsafterinactivatedsarscov2vaccination
AT chenyue earlyhumoralresponsesofhemodialysispatientsafterinactivatedsarscov2vaccination
AT fengyating earlyhumoralresponsesofhemodialysispatientsafterinactivatedsarscov2vaccination
AT panhaifeng earlyhumoralresponsesofhemodialysispatientsafterinactivatedsarscov2vaccination
AT wangdeguang earlyhumoralresponsesofhemodialysispatientsafterinactivatedsarscov2vaccination